



Enfermedades Infecciosas y Microbiología Clínica

www.elsevier.es/eimc



Consensus statement

Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015[☆]



José Antonio Iribarren*, Rafael Rubio, Koldo Aguirrebengoa, Jose Ramón Arribas, Josu Baraia-Etxaburu, Félix Gutiérrez, Juan Carlos Lopez Bernaldo de Quirós, Juan Emilio Losa, José M^a Miró, Santiago Moreno, José Pérez Molina, Daniel Podzamczar, Federico Pulido, Melchor Riera, Antonio Rivero, José Sanz Moreno, Concha Amador, Antonio Antela, Piedad Arazo, Julio Arrizabalaga, Pablo Bachiller, Carlos Barros, Juan Berenguer, Joan Caylá, Pere Domingo, Vicente Estrada, Hernando Knobel, Jaime Locutura, José López Aldegue, Josep M^a Llibre, Fernando Lozano, Josep Mallolas, Eduardo Malmierca, Celia Miralles, Pilar Miralles, Agustín Muñoz, Agustín Ocampo, Julián Olalla, Inés Pérez, M^a Jesús Pérez Elías, José Luis Pérez Arellano, Joaquín Portilla, Esteban Ribera, Francisco Rodríguez, Miguel Santín, Jesús Sanz Sanz, M^a Jesús Téllez, Miguel Torralba, Eulalia Valencia, Miguel Angel Von Wichmann, GESIDA/SEIMC Writing Committee¹

ARTICLE INFO

Keywords:

Opportunistic infections
HIV infection
AIDS

ABSTRACT

Opportunistic infections continue to be a cause of morbidity and mortality in HIV-infected patients. They often arise because of severe immunosuppression resulting from poor adherence to antiretroviral therapy, failure of antiretroviral therapy, or unawareness of HIV infection by patients whose first clinical manifestation of AIDS is an opportunistic infection.

The present article is an executive summary of the document that updates the previous recommendations on the prevention and treatment of opportunistic infections in HIV-infected patients, namely, infections by parasites, fungi, viruses, mycobacteria, and bacteria, as well as imported infections. The article also addresses immune reconstitution inflammatory syndrome. This document is intended for all professionals who work in clinical practice in the field of HIV infection.

© 2016 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Executive summary: Prevención y tratamiento de infecciones oportunistas y otras coinfecciones en pacientes infectados por el VIH: mayo de 2015

RESUMEN

Las infecciones oportunistas siguen siendo una causa importante de morbi mortalidad en pacientes con infección por VIH. Ello ocurre en muchos casos debido a la inmunodepresión grave, bien ante la falta de adherencia al tratamiento antirretroviral, el fracaso del mismo o el desconocimiento de la existencia de la infección por el VIH en pacientes que comienzan con una infección oportunista.

Palabras clave:

Infecciones oportunistas
Infección por VIH
Sida

[☆] Readers who prefers to have this review in Castilian, can be obtained from the following address: <http://www.gesida-seimc.org/contenidos/guiasclinicas/2015/gesida-guiasclinicas-2015-InfeccionesOportunistasyCoinfeccionesVIH.pdf>

* Corresponding author.

E-mail address: joseantonio.iribarrenloyarte@osakidetza.eus (J.A. Iribarren).

¹ See Appendix A for the contributions of the Authors and Reviewers.

Este artículo es un resumen del documento de consenso que actualiza las recomendaciones previas de GESIDA respecto a la prevención y el tratamiento de las diferentes infecciones oportunistas en pacientes infectados por VIH: parasitarias, fúngicas, víricas, micobacterianas, bacterianas e importadas, además del síndrome de reconstitución inmune. Está dirigido a los profesionales que trabajan en la práctica clínica en el campo del VIH, con el objetivo de facilitarles una atención de calidad en la prevención y tratamiento de estas infecciones

© 2016 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Todos los derechos reservados.

Introduction

Opportunistic infections (OIs) have been the main cause of morbidity and mortality in HIV-infected patients since the beginning of the HIV epidemic.

Efficacious regimens for primary and secondary prophylaxis to prevent OIs were the first major advance in therapy for HIV-infected patients, significantly decreasing mortality, even before the advent of highly active antiretroviral therapy (ART). ART brought about a notable change in the progression of HIV infection by dramatically reducing mortality and the incidence of OIs. However, today, we continue to see cases of OI in various settings: patients who are unaware of their HIV infection and whose first manifestation is an OI; patients who do not receive ART; and failure of ART due to poor adherence or other causes. Accordingly, treatment of OIs continues to be a relevant topic in the care of HIV-infected patients¹.

The present document is an update of our previous recommendations on prevention and treatment of OIs in HIV-infected patients. The strength of the recommendation and ranking of the tests that support it are based on a modification of the criteria of the *Infectious Diseases Society of America*. According to these criteria, each recommendation should be offered always (A), generally (B), or optionally (C), based on data from 1 or more randomized clinical trials with clinical or laboratory results (I), 1 or more nonrandomized trials or observational cohort data (II), or expert opinion (III).

Owing to space limitations, we strongly recommend to the reader to consult the tables of the leading document, which display the various prophylaxis and treatment regimens (both preferred and alternative) and the corresponding doses. Available at <http://www.gesida-seimc.org/contenidos/guiasclinicas/2015/gesida-guiasclinicas-2015-InfeccionesOportunistasyCoinfeccionesVIH.pdf>.

Parasitic infections

Toxoplasma gondii

Patients who have not been exposed to *Toxoplasma gondii* (confirmed by a negative anti-*Toxoplasma gondii* IgG result) should avoid contact with the parasite.

- Handwashing is recommended after contact with animals, especially cats, and after handling raw meat. Patients should try to eat meat that has been adequately cooked (or previously frozen to -20°C) and wash fruit and vegetables that are to be eaten raw (BIII).
- Primary prophylaxis should be with cotrimoxazole in patients with anti-*Toxoplasma gondii* IgG and a CD4+ T-lymphocyte count <100 cells/ μL (AII); alternatives include pyrimethamine combined with dapsone or atovaquone.
- When cerebral toxoplasmosis is suspected, treatment should be started with sulfadiazine combined with pyrimethamine (and folinic acid to reduce blood toxicity) (AI) and maintained for at

least 6 weeks (BII). A brain biopsy should be performed if no response is observed at 7–14 days.

- Once treatment is complete, secondary prophylaxis can be started (same regimen, reduced dose) (AI).
- Prophylaxis can be discontinued after 6 months on ART, providing the patient has maintained an undetectable viral load and a CD4+ T-lymphocyte count >200 cells/ μL for ≥ 3 months (primary) or ≥ 6 months (secondary) (AI), probably owing to recovery of the anti-*Toxoplasma gondii* cellular response (CD4+ T lymphocytes). Prophylaxis should be restarted if the CD4+ T-lymphocyte count returns to <100 – 200 cells/ μL (AIII).

Leishmania species

- The treatment of choice for visceral leishmaniasis is liposomal amphotericin B (AII) or amphotericin B lipid complex, in various regimens. Alternatives include amphotericin B deoxycholate (renal toxicity) or pentavalent antimonials (pancreatic and cardiac toxicity) (BII). The efficacy of miltefosine and paromomycin has not been demonstrated in HIV-infected patients (CIII).
- Secondary prophylaxis should be administered once the acute infection has been treated (BII). Lipid formulations of amphotericin B (liposomal [AII] or lipid complex [BI]) are also drugs of choice.
- No safe recommendation can be made about withdrawal of secondary prophylaxis against *Leishmania*. Although some experts recommend maintaining prophylaxis indefinitely, suspension should be considered in patients who remain relapse-free for 6 months, maintain a CD4+ T-lymphocyte count >200 – 350 cells/ μL and an undetectable viral load for >3 months, and, if possible, test negative in PCR for the *Leishmania* antigen in blood or urine (CIII). Prophylaxis should be restarted if the CD4+ T-lymphocyte count falls to <200 cells/ μL .

Cryptosporidium species, microsporidia, and Isospora belli

- There are no efficacious primary prophylaxis regimens.
- There is no specific treatment for cryptosporidiosis (CIII), and cure is based on ART-associated immune recovery (AII).
- Treatment of microsporidiosis also depends on ART (AII), although efficacious complementary drugs are available: in intestinal infections and infections caused by *Enterocytozoon bieneusi*, the treatment of choice is oral fumagillin (BIII); albendazole is recommended if other species are involved (AII). In patients with ocular involvement, albendazole can be combined with topical fumagillin (BIII).
- The treatment of choice for isosporiasis is cotrimoxazole (BI).
- Secondary prophylaxis for microsporidiosis and isosporiasis involves maintaining the same regimen as for treatment. This can be suspended when a CD4+ T-lymphocyte count >200 cells/ μL is reached after 6 months of efficacious ART (CIII and BIII).

Download English Version:

<https://daneshyari.com/en/article/3400493>

Download Persian Version:

<https://daneshyari.com/article/3400493>

[Daneshyari.com](https://daneshyari.com)